Twist Bioscience Corporation Company Profile
NASDAQ: TWSTHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Twist Bioscience at a glance
Twist Bioscience Corporation (NASDAQ: TWST) is a Biotechnology company in the Healthcare sector headquartered in South San Francisco, CA. Twist Bioscience is led by Dr. Emily Marine Leproust Ph.D. and employs about 979 people. The company's shares have traded publicly since 2018.
At a market capitalization of $10.08 billion, it is considered a large-cap company. Its SEC Central Index Key (CIK) is 0001581280, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Twist Bioscience do?
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc and Lilly TuneLab. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Business description based on the company's public filings.
Company information
- Legal name
- Twist Bioscience Corporation
- Ticker
- NASDAQ: TWST
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Emily Marine Leproust Ph.D.
- Employees
- 979
- Headquarters
- 681 Gateway Boulevard, South San Francisco, CA, United States
- Phone
- 800 719 0671
- Website
- twistbioscience.com
- IPO year
- 2018
- Market cap
- $10.08B
- SEC CIK
- 0001581280
Companies similar to Twist Bioscience
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KRYSKrystal Biotech Inc. | 327.30 | +0.84% | $9.69B | vs TWST |
| PCVXVaxcyte Inc. | 65.02 | -2.90% | $9.67B | vs TWST |
| ABVXAbivax SA ADR | 89.05 | +2.34% | $7.77B | vs TWST |
| COGTCogent Biosciences Inc. | 30.08 | -0.20% | $5.22B | vs TWST |
| TVTXTravere Therapeutics Inc. | 52.04 | -2.62% | $4.91B | vs TWST |
| EWTXEdgewise Therapeutics Inc. | 39.23 | -0.86% | $4.26B | vs TWST |
| IDYAIDEAYA Biosciences Inc. | 36.06 | -0.55% | $3.48B | vs TWST |
| PGENPrecigen Inc. | 7.60 | +0.80% | $2.72B | vs TWST |